Sanofi is set to acquire Qunol®, a prominent U.S. brand in the health and wellness sector. This transaction strengthens Sanofi’s Consumer Healthcare’s (CHC) Vitamin, Mineral, and Supplements (VMS) category, targeting the active ‘healthy aging’ segment. The addition of Qunol’s CoQ10 and Turmeric products expands Sanofi’s portfolio, tapping into the growing demand for chronic condition management and proactive preventive health. The deal is expected to close in Q3 2023, supporting Sanofi’s growth and value creation in the consumer healthcare business.
Sanofi to acquireQunol®,a fast-growing U.S. brand in the healthy aging segment
- Transaction brings Qunol®, a trusted, profitable double-digit growth and market-leading brand in health & wellness to Sanofi’s CHC U.S. portfolio
- Addition of Qunol’s CoQ10 and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Paris, July28, 2023. Sanofi announces today it has entered into a definitive agreement to acquire ownership of Qunol®, a U.S.-based, market-leading brand in health & wellness. This transaction will strengthen Sanofi’s Consumer Healthcare’s (CHC) Vitamin, Mineral and Supplements (VMS) category, one of the largest and fastest-growing consumer health categories in the U.S., focusing on the active ‘healthy aging’ segment. With Qunol’s CoQ10 in heart health and Turmeric in joint health, CHC at Sanofi adds a trusted, profitable double-digit growth brand to its U.S. portfolio, focused on chronic conditions with growing consumer demand. With this acquisition, Sanofi continues to pursue growth opportunities and value creation for its consumer healthcare business.
Julie Van Ongevalle
Executive Vice President, Consumer Healthcare, Sanofi
“The acquisition of Qunol further strengthens our portfolio in the wellness category. Ittaps into the growing ‘healthy aging’ segment and fills one of our white spaces in the US, unlocking an opportunity for us to build on our U.S. presence and accelerate our growth. VMS now functions as long-term support for overall health and wellness whereproactive preventive health has become the new normpost-pandemic.We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Qunol CoQ10 and Turmeric products are both backed by science literature and strong market positioning in their segments. Qunol’s high product quality and efficacy have resulted in strong brand equity among consumers and customers, as well as above category consumer loyalty. The Qunol brand will benefit from Sanofi’s CHC resources to expand into other chronic conditions and develop its footprint outside the U.S.
Peter Boutros
CEO, Quten Research Institute, LLC
“Qunol is looking forward to joining Sanofi’s consumer healthcare team and developing synergies that will further drive brand awarenessfor our productswith our consumers and customers.With Sanofi, we have the opportunity to further grow in the U.S. and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength.”
Transaction terms
Sanofi entered into a definitive agreement to acquire ownership of Qunol, subject to customary closing conditions, including applicable regulatory approvals. The acquisition is expected to close Q3 2023.
Source: BioSpace
